Basseri Robert J, Weitsman Stacy, Barlow Gillian M, Pimentel Mark
Dr. Basseri, Ms. Weitsman, and Dr. Barlow are affiliated with the GI Motility Program at Cedars-Sinai Medical Center in Los Angeles, California, where Dr. Pimentel serves as Director.
Gastroenterol Hepatol (N Y). 2011 Jul;7(7):455-93.
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder with an estimated worldwide prevalence of 10-20%. IBS can be associated with severe gastrointestinal symptoms, including abdominal pain, bloating, and altered bowel function. Although the causes of IBS remain undefined, recent research has increasingly suggested roles for gut flora in IBS. These roles involve postinfectious IBS, which can occur after a single episode of acute gastroenteritis, and small intestinal bacterial overgrowth, in which elevated populations of aerobic and anaerobic bacteria cause abdominal pain and altered bowel function. More recently, potential roles for methanogens in contributing to IBS subtypes have also been identified. In this paper, we review the different mechanisms by which gut flora may contribute to IBS and also discuss the efficacy and safety of various antibiotic therapies for treating IBS symptoms.
肠易激综合征（IBS）是一种常见的功能性胃肠疾病，全球估计患病率为10%-20%。IBS可能伴有严重的胃肠道症状，包括腹痛、腹胀和肠道功能改变。尽管IBS的病因尚不明确，但最近的研究越来越多地表明肠道菌群在IBS中发挥作用。这些作用包括感染后IBS，其可在单次急性肠胃炎发作后发生，以及小肠细菌过度生长，其中需氧菌和厌氧菌数量增加会导致腹痛和肠道功能改变。最近，还发现了产甲烷菌在IBS亚型中的潜在作用。在本文中，我们综述了肠道菌群可能导致IBS的不同机制，并讨论了各种抗生素治疗IBS症状的疗效和安全性。
